{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Back Bay Life Science Report","title":"ADC Revolution in Ovarian Cancer: Current Developments and Future Outlook","html":"","width":"100%","height":180,"duration":1793,"description":"As ovarian cancer research enters a pivotal new era, Back Bay Life Science Advisors' Dr. Pete Bak is joined by Director Mavra Nasir and Consultant Trent Gordon for a deep dive into one of oncology's most active and rapidly evolving therapeutic landscapes.\n\nDespite ranking as one of the top causes of cancer death among women worldwide—with a five-year survival rate still hovering around 50%—ovarian cancer has historically suffered from a sparse treatment pipeline. That is changing fast. This episode traces the field's major inflection points, from the landmark approvals of bevacizumab and PARP inhibitors in 2014, to the game-changing 2022 ADC approval of Elahere, to the recent Keytruda approval in high PD-L1 expressors—and looks ahead to a wave of innovation that could fundamentally reshape how patients are treated.\n\nPete, Mavra, and Trent break down the competitive ADC landscape, discuss next-generation entrants targeting folate receptor alpha and beyond, and examine what a crowded pipeline means for clinical development strategy in a space where the standard of care is moving fast.\nPodcast topics include:\nThe ovarian cancer patient landscape: why late-stage diagnosis remains the norm and what that means for treatment\nKey historical milestones in ovarian cancer drug development and why the pace of innovation is now accelerating\nElahere's approval, efficacy profile, and the real-world challenges of ocular toxicity and patient eligibility\nNext-generation folate receptor alpha ADCs from Genmab, Lilly, and AstraZeneca—and how they may differentiate on payload, ORR, and sequencing\nEmerging targets beyond folate receptor alpha: B7H3, B7H4, NAPI2B, and CDH6\nThe role of ADC stacking and sequencing as the platinum-resistant setting becomes increasingly crowded\nBispecific antibodies and the potential to convert immunologically \"cold\" ovarian tumors into candidates for immunotherapy\nAbbVie's strategy to expand Elahere into earlier lines of therapy\nHow clinical trial...","thumbnail_url":"https://img.transistorcdn.com/W6Lngt-BhnFN8FVt3HSPeq-NUJHgo4jaJncMb2aU6_E/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS81NjE3/MTc3NDg3NzgyNTI0/ODE3Y2ViM2Q4OWI5/MDUzMC5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}